Jiangsu Hengrui Pharmaceuticals Co., Ltd. Receives Approval for SHR‑1049 Injection Clinical Trial
Regulatory Update
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code 600276) announced that the National Medical Products Administration (NMPA) has issued a Notice of Approval for the clinical trial of SHR‑1049 Injection. The company will begin the clinical trial shortly, according to the board’s statement.
The announcement confirms that the company’s board and directors affirm the accuracy of the information and acknowledge legal responsibility for any inaccuracies or omissions.
Implications for the Company
- Research & Development Progress: SHR‑1049 Injection is a new therapeutic candidate that will undergo phase I/II studies. Successful trials could add a new product line to Hengrui’s portfolio of anti‑tumor, pain‑killer, and anti‑infection medicines.
- Investment Signal: Approval of a clinical trial is a positive development for investors, indicating that the company is advancing its pipeline and could potentially enhance future revenue streams.
Market Context
On January 27, 2026, the medical‑biological sector in China experienced a modest decline of 1.11 %. Despite this, the industry remained a target for capital inflows, with net inflows of 28.39 billion CNY reported on January 26 for the broader medical‑biological industry. This suggests that investor interest in pharmaceutical development remains resilient even amid short‑term market volatility.
Company Overview
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is headquartered in Lianyungang, China. The company specializes in developing, manufacturing, and marketing a range of medicines and packaging materials, including anti‑tumor drugs, analgesics, and anti‑infection agents. It is listed on the Shanghai Stock Exchange and trades in Hong Kong under the ticker H‑share. As of the close on January 25, 2026, its share price stood at HKD 71.95, with a market capitalization of approximately HKD 439.71 billion. The firm’s price‑earnings ratio was 53.27.
